1. Home
  2. UTZ vs CGEM Comparison

UTZ vs CGEM Comparison

Compare UTZ & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Utz Brands Inc

UTZ

Utz Brands Inc

HOLD

Current Price

$7.69

Market Cap

912.7M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.30

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTZ
CGEM
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
912.7M
794.7M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
UTZ
CGEM
Price
$7.69
$14.30
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$13.00
$30.11
AVG Volume (30 Days)
1.8M
696.1K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.33%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$1,438,800,000.00
N/A
Revenue This Year
$5.09
N/A
Revenue Next Year
$1.52
$79.85
P/E Ratio
$772.00
N/A
Revenue Growth
2.09
N/A
52 Week Low
$7.12
$5.68
52 Week High
$14.67
$16.74

Technical Indicators

Market Signals
Indicator
UTZ
CGEM
Relative Strength Index (RSI) 41.32 55.13
Support Level $7.19 $11.43
Resistance Level $10.74 $16.74
Average True Range (ATR) 0.30 0.87
MACD 0.11 0.01
Stochastic Oscillator 63.69 80.91

Price Performance

Historical Comparison
UTZ
CGEM

About UTZ Utz Brands Inc

Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: